A Phase 3, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of ITCA 650 to Sitagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 24 Dec 2012
At a glance
- Drugs Exenatide (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 24 Dec 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 18 Oct 2012 Planned End Date changed from 1 Jul 2013 to 1 Jul 2014, as reported by ClinicalTrials.gov.